Health Trials

Ivonescimab

3

Review clinical trials related to Ivonescimab. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 15, 2026Locations: 1
Eligibility criteria

Participants with histologically or cytologically confirmed metastatic/advanced... [+18]

Participants must not have any other malignancies within the past 2 years except... [+26]

Read more
Status: Recruiting

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Participants needed: 45
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tang-Du HospitalUpdated: Feb 3, 2026Locations: 1
Eligibility criteria

Informed Consent: Written informed consent must be obtained before any study-rel... [+10]

History of Other Malignancies: Participants who have had any other malignancy wi... [+12]

Read more
Status: Not yet recruiting

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

This study is a multicenter, open-label phase II trial conducted to assess the safety and antitumor activity of Ivonescimab (AK112) plus FOLFIRI versus bevacizumab plus FOLFIRI as second-line treatment in subjects with MSS/pMMR metastatic colorectal cancer who have experienced intolerance to oxaliplatin-containing first-line therapy or disease progression, or recurrence within 6 months after oxaliplatin adjuvant therapy.

Participants needed: 130
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jun 15, 2025
Eligibility criteria

Voluntarily sign written informed consent [+18]

1.Known as MSI-H or dMMR status 2.History of or concurrent malignancies within 3...

Read more